HEALI rolls out PAINASSAY™;

Helping pain sufferers manage their pain more effectively

19 January 2014

Nearly 1 in 5 adults in Europe suffers from long‐term pain – at least 75 million people. And studies report that between half and two-thirds of people with chronic pain in a are less able or unable to exercise, enjoy normal sleep, perform household chores, attend social activities, drive a car, walk or have sexual relations. Thus the efficient management of pain is eminent.

 

However, the same studies show that more than 60 percent of European pain patients report their treatment is inadequate with 50 percent of them endure inadequate pain relief for at least two years. The reason being that based on their genetic blueprint people react and metabolize pain killers differently. However most clinicians do not have sufficient genetic data from the individual patient to assess which drugs will be suitable for this person, and help them better manage their pain.

 

PAINASSAY™ guides pain sufferers and their physicians to identify which pain treatments will be most effective. The test looks for specific biomarkers in the patient’s genetic (DNA) code, which tell us about the way in which their body processes pain medications. It enables the patient and their physician to select the pain medications that are likely to work most compatibly with the individual patient’s body and so are more likely to be effective for them.

 

 

HEALI LIMITED

 

ST JOHN'S INNOVATION CENTRE

COWLEY ROAD

CAMBRIDGE

CB4 0WS

UNITED KINGDOM

 

 

HEALI Limited is a company registered in England no. 08693232